Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1999 February; 79(3-4): 658–665.
PMCID: PMC2362441

Patterns of care and survival for adolescents and young adults with acute leukaemia – a population-based study


We report a population-based study of patterns of care and survival for people with acute leukaemia diagnosed at age 15–29 years during 1984–94 in regions of England and Wales covered by specialist leukaemia registries. There were 879 patients: 417 with acute lymphoblastic leukaemia (ALL) and 462 with acute myeloid leukaemia (AML). For ALL, actuarial survival rates were 43% at 5 years after diagnosis and 37% at 10 years. Survival improved significantly between 1984–88 and 1989–94 for those aged 15–19 at diagnosis. Patients entered in national clinical trials and those not entered had similar survival rates. Survival rates were similar at teaching and non-teaching hospitals and at hospitals treating different numbers of study patients per year. For AML, survival rates were 42% at 5 years after diagnosis and 39% at 10 years. Survival improved significantly between 1984–88 and 1989–94. Patients entered in the Medical Research Council AML10 trial had a higher survival rate than those who were in the earlier AML9 trial. Survival did not vary with category of hospital. We conclude that survival has improved for adolescents and young adults with acute leukaemia but that there is at present no evidence that centralized treatment results in a survival benefit for patients in this age group. © 1999 Cancer Research Campaign

Keywords: acute leukaemia, survival rates, place of treatment, clinical trials

Full Text

The Full Text of this article is available as a PDF (86K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Schneider U, van Lessen A, Huhn D, Serke S. Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. Br J Haematol. 1997 Apr;97(1):56–64. [PubMed]
  • Chessells JM, Hall E, Prentice HG, Durrant J, Bailey CC, Richards SM. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia. 1998 Apr;12(4):463–473. [PubMed]
  • Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG, Burnett AK. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997 Apr 1;89(7):2311–2318. [PubMed]
  • Haward RA. Establishing cancer units. Br J Cancer. 1995 Sep;72(3):531–534. [PMC free article] [PubMed]
  • Kerr DJ, Griffiths R, Edwards B. Delivering cancer care: a model from the West Midlands. Br J Cancer. 1996 Sep;74(5):667–669. [PMC free article] [PubMed]
  • Proctor SJ. Acute lymphoblastic leukaemia in adults: the case for a strategic shift in study approach. Br J Haematol. 1994 Oct;88(2):229–233. [PubMed]
  • Proctor SJ, Taylor P, Thompson RB, Finney R, Reid MM, Hamilton PJ, Saunders P, Fail B, Dickinson A, Paul B, et al. Acute lymphoblastic leukaemia in adults in the northern region of England--a study of 75 cases. Q J Med. 1985 Nov;57(223):761–774. [PubMed]
  • Proctor SJ, Taylor PR, Stark A, Carey PJ, Bown N, Hamilton PJ, Reid MM. Evaluation of the impact of allogenic transplant in first remission on an unselected population of patients with acute myeloid leukaemia aged 15-55 years. The Northern Regional Haematology Group. Leukemia. 1995 Jul;9(7):1246–1251. [PubMed]
  • Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol. 1997 Mar;96(3):601–610. [PubMed]
  • Selby P, Gillis C, Haward R. Benefits from specialised cancer care. Lancet. 1996 Aug 3;348(9023):313–318. [PubMed]
  • Stiller CA. Population based survival rates for childhood cancer in Britain, 1980-91. BMJ. 1994 Dec 17;309(6969):1612–1616. [PMC free article] [PubMed]
  • Stiller CA. Centralised treatment, entry to trials and survival. Br J Cancer. 1994 Aug;70(2):352–362. [PMC free article] [PubMed]
  • Stiller CA, Draper GJ. Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia. Arch Dis Child. 1989 May;64(5):657–661. [PMC free article] [PubMed]
  • Stiller CA, Eatock EM. Survival from acute non-lymphocytic leukaemia, 1971-88: a population based study. Arch Dis Child. 1994 Mar;70(3):219–223. [PMC free article] [PubMed]
  • Taylor Irving. Problems of site specific cancer specialisation. BMJ. 1996 Nov 09;313(7066):1213–1213. [PMC free article]
  • Warrell RP, Jr, Frankel SR, Miller WH, Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991 May 16;324(20):1385–1393. [PubMed]
  • Youngson JH, Jones JM, Chang JG, Harris M, Banergee SS. Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study. Br J Cancer. 1995 Sep;72(3):757–765. [PMC free article] [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK